Eliem Therapeutics, Inc - Common Stock (NQ:ELYM)

5.110 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eliem Therapeutics, Inc - Common Stock

< Previous 1 2 3 4 Next >

Why Is Discover Financial (DFS) Stock Down 13% Today? ↗

July 20, 2023

Discover Financial (DFS) stock is falling on Thursday after the financial services company revealed it's undergoing a regulatory review.

Via InvestorPlace

Why Is Netcapital (NCPL) Stock Down 42% Today? ↗

July 20, 2023

Netcapital (NCPL) stock is dropping on Thursday after the fintech company announced the pricing of a public share offering.

Via InvestorPlace

Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today? ↗

July 20, 2023

Eliem Therapeutics (ELYM) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

July 20, 2023

It's time to start off the day with a breakdown of the biggest pre-market stock movers worth watching on Thursday morning!

Via InvestorPlace

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

July 20, 2023

From Eliem Therapeutics, Inc.

Via GlobeNewswire

Eliem Pauses Development On Depression Drug, Lays Off 55% Workforce ↗

February 10, 2023

Via Benzinga

Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study ↗

October 05, 2022

Via Benzinga

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

May 11, 2023

From Eliem Therapeutics, Inc.

Via GlobeNewswire

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

March 06, 2023

From Eliem Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

February 23, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 20, 2023

Via Benzinga

Eliem Therapeutics: Q2 Earnings Insights ↗

August 15, 2022

Eliem Therapeutics (NASDAQ:ELYM) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Eliem Therapeutics Shares Fall On Lower Back Pain Trial Setback ↗

August 02, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 17, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2023 ↗

February 10, 2023

Via Benzinga

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

February 09, 2023

From Eliem Therapeutics, Inc.

Via GlobeNewswire

Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 04, 2023

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive...

Via Benzinga

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

November 30, 2022

From Eliem Therapeutics, Inc.

Via GlobeNewswire

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

November 14, 2022

From Eliem Therapeutics, Inc.

Via GlobeNewswire

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

November 08, 2022

From Eliem Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022 ↗

October 28, 2022

Upgrades

Via Benzinga

Eliem Therapeutics Provides Update on Pipeline Progress

October 05, 2022

From Eliem Therapeutics, Inc.

Via GlobeNewswire

Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday ↗

September 23, 2022

Gainers

Via Benzinga

SVB Leerink Maintains Outperform Rating for Eliem Therapeutics: Here's What You Need To Know ↗

August 16, 2022

SVB Leerink has decided to maintain its Outperform rating of Eliem Therapeutics (NASDAQ:ELYM) and lower its price target from $9.00 to $4.00. Shares of Eliem Therapeutics are trading down 2.08% over...

Via Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 02, 2022

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 02, 2022

Via Benzinga

Recap of Monday's Biotech Catalysts - End of the Day Summary ↗

July 18, 2022

Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...

Via Benzinga

Eliem Announces Updated Development Plans For Its Delayed Depression Candidate ↗

July 18, 2022

In April, Eliem Therapeutics Inc (NASDAQ: ELYM) delayed ETX-155 into Phase 2a depression trials to determine the root cause of a lower-than-expected exposure observed in a Phase 1b study in...

Via Benzinga

This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday ↗

July 25, 2022

Gainers

Via Benzinga

SVB Leerink Maintains Outperform Rating for Eliem Therapeutics: Here's What You Need To Know ↗

July 11, 2022

SVB Leerink has decided to maintain its Outperform rating of Eliem Therapeutics (NASDAQ:ELYM) and lower its price target from $13.00 to $9.00. Shares of Eliem Therapeutics are trading down 4.04% over...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.